Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more
Market Cap & Net Worth: Swedish Orphan Biovitrum AB (publ) (BIOVF)
Swedish Orphan Biovitrum AB (publ) (PINK:BIOVF) has a market capitalization of $9.94 Billion ($9.94 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #2337 globally and #1656 in its home market, demonstrating a 0.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Swedish Orphan Biovitrum AB (publ)'s stock price $28.75 by its total outstanding shares 345660592 (345.66 Million).
Swedish Orphan Biovitrum AB (publ) Market Cap History: 2015 to 2025
Swedish Orphan Biovitrum AB (publ)'s market capitalization history from 2015 to 2025. Data shows growth from $5.56 Billion to $9.94 Billion (6.79% CAGR).
Swedish Orphan Biovitrum AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Swedish Orphan Biovitrum AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.35x
Swedish Orphan Biovitrum AB (publ)'s market cap is 0.35 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
20.84x
Swedish Orphan Biovitrum AB (publ)'s market cap is 20.84 times its annual earnings
10.29x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.84 Billion | $5.20 Billion | $809.07 Million | 0.74x | 4.75x |
| 2017 | $5.09 Billion | $6.51 Billion | $1.15 Billion | 0.78x | 4.43x |
| 2018 | $7.17 Billion | $9.14 Billion | $2.42 Billion | 0.78x | 2.97x |
| 2019 | $5.62 Billion | $14.25 Billion | $3.30 Billion | 0.39x | 1.70x |
| 2020 | $6.76 Billion | $15.26 Billion | $3.25 Billion | 0.44x | 2.08x |
| 2021 | $7.05 Billion | $15.53 Billion | $2.68 Billion | 0.45x | 2.63x |
| 2022 | $7.31 Billion | $18.79 Billion | $2.64 Billion | 0.39x | 2.77x |
| 2023 | $9.07 Billion | $22.12 Billion | $2.41 Billion | 0.41x | 3.77x |
| 2024 | $9.41 Billion | $26.03 Billion | $3.88 Billion | 0.36x | 2.42x |
| 2025 | $9.94 Billion | $28.17 Billion | $476.80 Million | 0.35x | 20.84x |
Competitor Companies of BIOVF by Market Capitalization
Companies near Swedish Orphan Biovitrum AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Swedish Orphan Biovitrum AB (publ) by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Swedish Orphan Biovitrum AB (publ) Historical Marketcap From 2015 to 2025
Between 2015 and today, Swedish Orphan Biovitrum AB (publ)'s market cap moved from $5.56 Billion to $ 9.94 Billion, with a yearly change of 6.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.94 Billion | +5.58% |
| 2024 | $9.41 Billion | +3.73% |
| 2023 | $9.07 Billion | +24.11% |
| 2022 | $7.31 Billion | +3.73% |
| 2021 | $7.05 Billion | +4.30% |
| 2020 | $6.76 Billion | +20.31% |
| 2019 | $5.62 Billion | -21.69% |
| 2018 | $7.17 Billion | +40.97% |
| 2017 | $5.09 Billion | +32.37% |
| 2016 | $3.84 Billion | -30.81% |
| 2015 | $5.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Swedish Orphan Biovitrum AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.94 Billion USD |
| MoneyControl | $9.94 Billion USD |
| MarketWatch | $9.94 Billion USD |
| marketcap.company | $9.94 Billion USD |
| Reuters | $9.94 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.